Manufactures and markets pharmaceutical formulations across four primary geographies: India, the United States, emerging markets, and the rest of the world. India formulations are the largest stream, with Q1 FY27 sales of Rs 54,749m and the #1 position in the Indian Pharmaceutical Market at 8.5% share. The US business reported US$427m in Q1 FY27 (-9.7% YoY), split between generics under pricing pressure from Lenalidomide erosion and specialty Innovative Medicines, which crossed US$1bn in US sales in FY26 and is now larger than US generics. Global Innovative Medicines, led by Ilumya (IL-23 immunology biologic), Odomzo, Leqselvi (alopecia), and Unloxcyt (oncology), contributed 21.9% of Q1 FY27 sales and grew 12.4% YoY at US$351m. Emerging markets generated US$311m in Q1 FY27 (+4.2%) and ROW generated US$218m. It is also the #2 generic Semaglutide injectable player in India, with approvals secured in Brazil and South Africa. The pending Organon acquisition (closing targeted Q4 FY27) would add a women's health and established brands portfolio, and Innovcare Lifesciences was acquired for Rs 271.2 crores to strengthen the India product range. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. India formulations, US formulations, Emerging Markets formulations, Rest of World, Global Innovative Medicines (22%). Diversified specialty pharmaceuticals spanning branded generics, US generics, and a growing global Innovative Medicines franchise
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 38,654 | 43,886 | 48,497 | 52,578 | 58,462 |
| EBITDA (ex other income) | 5,831 | 11,475 | 12,529 | 14,594 | 16,424 |
| margin % | 15.1 | 26.1 | 25.8 | 27.8 | 28.1 |
| Owners' profit | 3,273 | 8,474 | 9,576 | 10,929 | 11,479 |
| EPS, as reported (₹) | 13.60 | 35.30 | 39.90 | 45.60 | 47.80 |
| ROE % · ROCE % | 6.6 · 8.8 | 14.4 · 15.7 | 14.3 · 16.5 | 15.1 · 18.9 | 13.7 · 17.9 |
| Debt / equity (x) | 0.02 | 0.10 | 0.04 | 0.03 | 0.05 |
| Cash from operations | 8,985 | 4,959 | 12,135 | 14,072 | 12,419 |
| Capex | (1,495) | (2,086) | (2,202) | (2,129) | (3,609) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 | 15,521 | 14,612 | 15,300 |
| Profit before tax | 3,598 | 3,476 | 3,254 | 3,173 | 4,168 | 4,227 | 3,551 | 4,099 |
| Net profit | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 | 2,710 | 2,901 |
| EPS (₹) | 12.70 | 12.10 | 9.00 | 9.50 | 13.00 | 14.00 | 11.30 | 12.10 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L ◆ | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Sun Pharma subsidiaries settle US antitrust pricing lawsuit | regulatory legal | high | — | — |
| 9 Sept 2026 · Sun Pharma sets up treasury subsidiary at GIFT City | strategic transactions | low | — | — |
| 8 Sept 2026 · Sun Pharma gets investment grade ratings with stable outlooks | credit debt | medium | — | — |
| 3 Sept 2026 · Schedule of upcoming analyst and investor meetings in September 2026 | board shareholder meetings | low | — | — |
| 31 Aug 2026 · Sun Pharma joins White House deal on U.S. medicine pricing | business updates | medium | — | — |
| 26 Aug 2026 · Postal Ballot notice published, e-voting from 19 to 26 September | compliance | minimal | — | — |
| 25 Aug 2026 · Postal ballot to reclassify Valia family members from Promoter Group to Public | ownership changes | medium | — | — |
| 25 Aug 2026 · Sun Pharma schedules investor meeting for 1 September 2026 | board shareholder meetings | low | — | — |
| 6 Aug 2026 · Sun Pharma gets NSE and BSE nod for promoter group reclassification | ownership changes | medium | — | — |
| 6 Aug 2026 · Sun Pharma Q1 FY27 earnings call: sales up 10.1%, US dips on Lenalidomide | investor communications | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 14.5 |
| 17.3 |
| 18.0 |
| 12.4 |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 36.5 | 28.9 | 101 of 169 | 41% |
| P/B | 5.3 | 3.3 | 120 of 163 | 27% |
| ROCE | 17.6 | 10.8 | 46 of 183 | 75% |
| ROE | 13.7 | 10.4 | 57 of 171 | 67% |
| Debt / Equity | 0.1 | 0.1 | 72 of 171 | 58% |
| EBITDA margin | 32.3 | 17.5 | 27 of 165 | 84% |
| Revenue growth | 10.5 | 16.3 | 93 of 161 | 43% |
| Profit growth | 26.5 | 30.9 | 84 of 158 | 47% |
| Market cap | 441471 | 839 | 1 of 182 | 100% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
